Article information
Abstract
Toxicity secondary to checkpoint inhibitors (ICP) can affect numerous parts of the body, with varying frequency. We present a case of bilateral optic neuritis secondary to the use of pembrolizumab (an anti-PD-1), which has been described in the literature in less than 1% of cases associated with the use of anti-PD-1/PD-L1 and anti-CTLA4 (ICP).
Keywords:
Optic neuritis
Check-Point Inhibitors (ICP)
Pembrolizumab
Lung cancer
Immune-related adverse events (irAEs)
Resumen
La toxicidad secundaria a Inhibidores del Check-Point (ICP) puede afectar a numerosas partes del organismo con una frecuencia variable. Presentamos a continuación un caso de neuritis óptica bilateral secundaria al uso de Pembrolizumab (fármaco antiPD-1), descrita en la literatura en menos del 1% de los casos en relación con el uso de fármacos antiPD-1/PD-L1 y antiCTLA4 (ICP).
Palabras clave:
Neuritis óptica
Inhibidores del Check-Point (ICP)
Pembrolizumab
Cáncer de pulmón
Efectos adversos relacionados con el sistema inmunitario (irAE)
Article
These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
